Posted by Michael Wonder on 26 Jun 2024
Health Canada authorizes Lilly's Ebglyss (lebrikizumab) for the treatment of moderate to severe atopic dermatitis in adults and adolescents 12 years and older
25 June 2024 - Patients treated with Ebglyss experienced significant skin clearance and itch relief as early as 4 weeks.
Eli Lilly Canada announced today that Health Canada authorised Ebglyss (lebrikizumab), a targeted IL-13 inhibitor, for the treatment of moderate-to-severe atopic dermatitis in adults and adolescents 12 years of age and older with a body weight of at least 40 kg, whose disease is not well controlled despite treatment with topical prescription therapies or when those therapies are not advisable.
